Monthly Archives: December 2021

Cell Biology

Chan Zuckerberg Initiative to pour $3.4B over 10 years into AI, imaging and other tech to unravel biomedical challenges – FierceBiotech

Five years into its lofty goal of funding projects to cure, prevent or manage all disease within our childrens lifetime, the Chan Zuckerberg Initiatives Biohub is getting a major boost.

The philanthropic initiativeled by the husband-and-wife duo of Facebook founder Mark Zuckerberg and Priscilla Chan, M.D., formerly a practicing pediatricianunveiled this week a 10-year plan to invest $3.4 billion in the development of new technologies and tools that help improve our understanding of human health and disease.

Between $800 million and $1 billion of the new funds will go to the Biohub, a CZI spokesperson told ABC News. The San Francisco-based research hub launched in 2016 with an initial commitment of about $600 million. Its first projects included the construction of the Cell Atlas, a map of the various types of cells that control each major organ, and the creation of the Infectious Disease Initiative to develop new diagnostic tests and vaccines to treat HIV, Ebola, Zika and other fast-spreading diseases.

The new funding will extend the hubs operations to at least 2031. Another $1 billion, meanwhile, will help create the CZ Biohub Network, which will fund and build new research centers focused on long-term biomedical projects, with the first groundbreaking slated for 2023.

Motivated in no small part by the pandemic, CZ Biohub will double down on efforts in both infectious disease and basic science by creating new technology platforms, foundational datasets and pipelines for cell biology at scale, while also expanding our pathogen detection efforts domestically and abroad, said Joe DeRisi, president of the research center.

RELATED: Zuckerberg and Chan latest wealthy philanthropists to attempt to cure all disease

Outside of the Biohub, CZI is devoting hundreds of millions more to establishing two other R&D facilities.

In addition to expanding our support for our core scientific programs in neurodegeneration, single-cell biology, imaging, open science, rare disease research and infectious disease research, over the next 10 years, CZI Science will focus on building new tools and technologies to measure human biology in action to benefit human health, Chan said in a statement.

To that end, the Chan Zuckerberg Institute for Advanced Biomedical Imaging, for one, will spend the next 15 years uniting a range of scientists and technologistswith expertise in areas spanning artificial intelligence to physics to biomedical engineeringto develop new imaging systems that give clinicians a clearer view of the inner workings of the human body. Itll receive between $600 million and $900 million to fund this work.

Finally, CZI will allot $500 million to the Kempner Institute for the Study of Natural and Artificial Intelligence, named for Zuckerbergs mother and based at Harvard University. There, researchers will study both artificial and human intelligence, using the latter to inform the development of new, smarter AI that learns, remembers, senses and adapts like the human brain.

RELATED: Chan Zuckerberg Initiative launches $17M digital imaging research program

To measure the human body in action with spatial accuracy, biochemical specificity and dynamic precision, we are going to need new instruments and analytical tools, said Zuckerberg.

"How can the application of artificial intelligence to biological imaging create new insights into how cells and tissues function? How do interactions between cancer cells, surrounding tissues and the immune system promote or prevent tumor growth? How do the brain and the body communicate to regulate physiological and emotional states? he continued. Working with the scientific community, we will create the teams, build the instruments and validate the uses that make these and other breakthroughs possible.

Read more from the original source:
Chan Zuckerberg Initiative to pour $3.4B over 10 years into AI, imaging and other tech to unravel biomedical challenges - FierceBiotech

Cell Biology

Fate Therapeutics Showcases Positive Interim Phase 1 Data from FT596 Off-the-shelf, iPSC-derived CAR NK Cell Program for Relapsed / Refractory B-cell…

5 of 6 Patients Achieve Objective Response, including 4 Patients with Complete Response, with Single Dose of FT596 at 900 Million Cells in Combination with Rituximab

13 of 19 Patients Achieve Objective Response with Single Dose of FT596 at 90 Million and 300 Million Cell Dose; 10 of 11 Patients Treated with a Second FT596 Cycle Continue in Ongoing Response, with 3 Patients in Ongoing Complete Response at 6 Months Follow-up; Additional 2 Patients Reach 6 Months in Complete Response

FT596 Treatment Regimens were Well-tolerated; No Dose-limiting Toxicities, and No Adverse Events of Any Grade of ICANS or GVHD, were Observed; Three Low-grade Adverse Events of CRS Resolved without Intensive Care Treatment

Company to Host Virtual Investor Event Tomorrow at 8:00 AM Eastern Time

SAN DIEGO, Dec. 13, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer, today showcased positive interim Phase 1 data from the Companys FT596 program for patients with relapsed / refractory B-cell lymphoma (BCL) at the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition. FT596 is the Companys off-the-shelf, multi-antigen targeted, iPSC-derived natural killer (NK) cell product candidate derived from a clonal master induced pluripotent stem cell (iPSC) line engineered with three anti-tumor functional modalities: a proprietary chimeric antigen receptor (CAR) optimized for NK cell biology that targets B-cell antigen CD19; a novel high-affinity, non-cleavable CD16 (hnCD16) Fc receptor that has been modified to prevent its down-regulation and to enhance its binding to tumor-targeting antibodies; and an IL-15 receptor fusion (IL-15RF) that augments NK cell activity.

The interim dose-escalation clinical data from our FT596 program in relapsed / refractory B-cell lymphoma demonstrate that off-the-shelf, iPSC-derived CAR NK cells can bring substantial therapeutic benefit to heavily pre-treated patients in urgent need of therapy, with high response rates and meaningful duration of responses, said Scott Wolchko, President and Chief Executive Officer of Fate Therapeutics. We are particularly pleased with the therapeutic profile that has emerged with FT596 in combination with rituximab, where over half of the patients treated with a single dose of FT596 at higher dose levels achieved a complete response with a favorable safety profile that is clearly differentiated from CAR T-cell therapy. We look forward to assessing a two-dose treatment schedule for FT596 to further define its potential best-in-class therapeutic profile and ability to reach more patients, including those earlier in care.

Story continues

The ongoing Phase 1 study in relapsed / refractory BCL is assessing a single dose of FT596 as monotherapy (Monotherapy Arm) and in combination with a single dose of rituximab (375 mg/m2) (Combination Arm) following three days of conditioning chemotherapy (500 mg/m2 of cyclophosphamide and 30 mg/m2 of fludarabine). Certain patients are eligible for re-treatment with a second, single-dose cycle.

The ASH presentation (Session 704Cellular Immunotherapies: Expanding Targets and Cellular Sources for Immunotherapies, Abstract 823) includes clinical data from 25 evaluable patients for safety (n=12 in Monotherapy Arm; n=13 in Combination Arm) in the first, second, and third single-dose cohorts of 30 million, 90 million, and 300 million cells, respectively, of which 24 patients were also evaluable for efficacy (n=12 in Monotherapy Arm; n=12 in Combination Arm), as of the data cutoff date of October 11, 2021. These 25 patients had received a median of four prior lines of therapy and a median of two prior lines containing CD20-targeted therapy. Of the 25 patients, 15 patients (60%) had aggressive B-cell lymphoma, 15 patients (60%) were refractory to most recent prior therapy, and 8 patients (32%) were previously treated with autologous CD19-targeted CAR T-cell therapy. Subsequent to the data cutoff date for the ASH presentation, an additional patient in the third single-dose cohort of the Combination Arm was evaluable for initial anti-tumor response, and seven patients in the fourth single-dose cohort of 900 million cells (n=1 in Monotherapy Arm; n=6 in Combination Arm) were evaluable for safety and initial anti-tumor response.

Single-dose, Single-cycle Response Data

In the second, third, and fourth dose cohorts of the Monotherapy and Combination Arms comprising a total of 26 patients, 18 patients (69%) achieved an objective response, including 12 patients (46%) that achieved a complete response, on Day 29 following a single dose of FT596 (see Table 1). Nine of these 26 patients were previously treated with autologous CD19-targeted CAR T-cell therapy and, of these nine patients, six achieved an objective response (67%) on Day 29 following a single dose of FT596. Notably, in the third and fourth dose cohorts of the Combination Arm comprising a total of 12 patients, nine patients (75%) achieved an objective response, including seven patients (58%) that achieved a complete response, on Day 29 following a single dose of FT596.

Durability of Response Data

The ASH presentation includes durability of response data from 13 responding patients in the second and third single-dose cohorts of 90 million cells and 300 million cells (n=9 in Monotherapy Arm; n=10 in Combination Arm). As of the data cutoff date of October 11, 2021, 10 patients continued in ongoing response, including three patients in ongoing complete response at least six months from initiation of treatment; two patients reached six months in complete response and subsequently had disease progression; and one patient had disease progression prior to six months. Of these 13 responding patients:

Monotherapy Arm (n=7 responding patients). Five patients, all of whom were treated with a second FT596 single-dose cycle with the consent of the U.S. Food and Drug Administration (FDA), continued in ongoing response at a median follow-up of 4.1 months, including one patient in ongoing complete response at 8.1 months; one patient, who was treated with only one FT596 single-dose cycle, reached six months in complete response and subsequently had disease progression at 6.5 months; and one patient, who was treated with only one FT596 single-dose cycle, had disease progression at 1.7 months.

Combination Arm (n=6 responding patients). Five patients, all of whom were treated with a second FT596 single-dose cycle with the consent of the FDA, continued in ongoing response at a median follow-up of 4.6 months, including two patients in ongoing complete response at 6.0 and 10.8 months; and one patient, who was treated with a second FT596 single-dose cycle with the consent of the FDA, reached six months in complete response and subsequently had disease progression at 6.7 months.

Table 1. FT596 Interim Phase 1 Data Day 29 Response Assessment 1

1 Dose x 1 Cycle

Monotherapy(n=13)

Combination(n=19)

Single-dose Level Cohorts (Cells)

OR

CR

OR

CR

30M

1/3 (33%)

0

0/3 (0%)

0

90M

3/4 (75%)

2

2/4 (50%)

2

300M 2

4/5 (80%)

1

4/6 (67%)

3

900M 2

0/1 (0%)

0

5/6 (83%)

4

aCD19 History (90M Cells)

n=10

n=16

Nave

7/9 (78%)

3

5/8 (63%)

4

Prior

0/1 (0%)

0

6/8 (75%)

5

Disease Histology (90M Cells)

n=10

n=16

Aggressive

1/3 (33%)

0

6/11 (55%)

4

Mantle cell

0/1 (0%)

0

2/2 (100%)

2

Indolent

6/6 (100%)

3

3/3 (100%)

3

aCD19 = autologous CD19-targeted CAR T-cell therapy; Aggressive = diffuse large B-cell lymphoma, Grade 3b follicular lymphoma, Richters transformation, and high-grade B-cell lymphoma; CR = complete response; Indolent = splenic diffuse red pulp small B-cell lymphoma, non-Grade 3b follicular lymphoma, Waldenstroms macroglobulinemia, and small lymphocytic lymphoma; M = million; OR = objective response1 As of data cutoff date of October 11, 2021, unless otherwise noted. Objective response and complete response are based on Cycle 1 Day 29 protocol-defined response assessment per Lugano 2014 criteria. Data subject to source document verification.2 Cycle 1 Day 29 protocol-defined response assessment completed subsequent to data cutoff date for one patient in the third single-dose cohort of 300 million cells in the Combination Arm and seven patients in the fourth single-dose cohort of 900 million cells (n=1 in Monotherapy Arm; n=6 in Combination Arm).

Safety Data

The FT596 treatment regimens were well tolerated, including in those patients treated with a second, single-dose cycle. No dose-limiting toxicities, and no treatment-emergent adverse events (TEAEs) of any grade of immune effector cell-associated neurotoxicity syndrome (ICANS) or graft-versus-host disease (GvHD) were observed. Three low-grade adverse events (two Grade 1, one Grade 2) of cytokine release syndrome (CRS) were reported, which were of limited duration and resolved without intensive care treatment (see Table 2).

The Company has initiated enrollment of a two-dose treatment schedule in the Combination Arm, with FT596 administered on Day 1 and Day 15 at 900 million cells per dose. Patients with clinical benefit following administration of the first two-dose cycle are eligible for re-treatment with a second two-dose cycle. Additionally, patients with clinical response are eligible for re-treatment following disease progression.

Table 2. FT596 Interim Phase 1 Data TEAEs of Interest

n (%)

Monotherapy(n=13)

Combination(n=19)

All Grade

Grade 3+

All Grade

Grade 3+

CRS

1 (8%)

---

2 (11%)

---

ICANS

---

---

---

---

GvHD

---

---

Continued here:
Fate Therapeutics Showcases Positive Interim Phase 1 Data from FT596 Off-the-shelf, iPSC-derived CAR NK Cell Program for Relapsed / Refractory B-cell...

Cell Biology

Live Cell Imaging Market Size, Future Trends, Current Growth 2022, Emerging Technologies, Global Regions with Industry Share Analysis, Gross Margin,…

Report Ocean presents a new report on Live Cell Imaging Market size, share, growth, industry trends, and forecast 2030, covering various industry elements and growth trends helpful for predicting the markets future.

Live cell imaging technology helps in studying live cells with the help of images taken from imaging systems, including high content screening systems and microscopes. To better understand the cells biological function by examining cellular dynamics, scientists have widely used this method. Many researchers have broadly accepted the technology of live cell imaging to gain better knowledge about cell biology in the past few years.

Request To Download Sample of This Strategic Report:-https://reportocean.com/industry-verticals/sample-request?report_id=BWCC433

The Live Cell Imaging Market is anticipated to grow at the rate of 9.1% CAGR by 2027. One of the prominent factors fueling the rising demand for this technology is the increasing concern for cancer. Few other factors including government initiatives to promote cell-based research, a wide range of applications of live cell imaging, increasing deployment of live cell imaging to understand dynamic processes and cellular structures, and to study various aspects such as cellular integrity, localization of molecules, enzyme activity, protein trafficking, exocytosis and endocytosis among others are likely to stimulate the market growth. However, the cost of implementing live cell imaging is huge, which is acting as a constraint for the market growth.

Live Cell Imaging Market based on ProductEquipmentConsumableSoftware

Live Cell Imaging Market based on ApplicationCell BiologyDevelopmental BiologyStem Cell & Drug DiscoveryOthers

Live Cell Imaging Market based on TechnologyTime-lapse MicroscopyFluorescence recovery after photobleaching (FRAP)Fluorescence resonance energy transfer (FRET)High content screening (HCS)Others

Live Cell Imaging Market based on GeographyNorth AmericaEuropeAsia PacificRest of the World

Request To Download Sample of This Strategic Report:-https://reportocean.com/industry-verticals/sample-request?report_id=BWCC433

Based on the product, the equipment segment has dominated the market. However, immense research being carried out to develop microscopes of higher resolution is likely to boost the segment growth. Advanced technologies such as inverted research-grade microscopes have allowed imaging of adherent cells and organelles and produce outcomes for tissue sections of less than 5 um thickness. Advanced developments are also enabling imaging of the cells in spatial resolutions within a time range.

The cell biology segment is leading the market on the basis of application. This is due to the increasing number of researchers working on molecular interaction networks. In addition, filter techniques and advanced illumination devices are innovations that further allow the procedure. Moreover, cell biologists use live cell imaging to understand the basic cellular structures and their interaction on the tissue level.

Further, the fluorescence resonance energy transfer segment is the significant segment based on the technology in the market. This is due to its advantage in ascertaining the spatial proximity at the protein level, which fluorescence microscopy cannot obtain. Furthermore, this technology has gained popularity in recent years due to its increasing application in genetic targeting peptides.

North America region is having a significant position in the market based on geography. The significant position is attributed to the rising demand for live cell imaging for drug discovery and increased products launched in this region. In drug discovery, the live cell imaging system helps understand the processes of cells, which offers an intensified picture of drug pharmacology.

Escalating demand of live cell imaging systems in drug discovery and government investments for evolution and advancements in live cell imaging systems are few major factors driving the growth of the global live cell imaging market. However, as knowing cellular structure and dynamic processes can be complicated in cell biology, the live cell imaging system solves this problem. Furthermore, as live cell usually offers more relevant information, it offers data about cell interaction, the behavior of single cells, and dynamics of cell organelles.

The leading vendors of the live cell imaging market are Thermo Fisher Scientific Inc., Nikon Instruments Inc., Molecular Devices, LLC, BioTek Instruments, Inc., PerkinElmer Inc., Bruker Corporation, General Electric, Olympus Corporation, CYTOSKELETON, INC. and Merck KGaA.

Get a Sample PDF copy of the report:-https://reportocean.com/industry-verticals/sample-request?report_id=BWCC433

Henceforth, live cell imaging technology has changed the way biologists study cells, proteins, and various processes and molecular interactions. Moreover, live cell imaging technology is majorly helpful in cell biology, which is a key concept in understanding the functions of cells.This report identifies the regions and segments projected to witness the highest CAGR rate and lead the market.The report also provides the analysis of geography focusing on the consumption of the product/service in the region coupled with the factors impacting the market in each region.This report gives the competitive outlook, which consists of the market ranking of the key players.Further present the information of recent product launches, partnerships, business expansions, and acquisitions of the market vendors.

What are the aspects of this report that relate to regional analysis?

The reports geographical regions include North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa.The report provides a comprehensive analysis of market trends, including information on usage and consumption at the regional level.Reports on the market include the growth rates of each region, which includes their countries, over the coming years.How are the key players in the market assessed?This report provides a comprehensive analysis of leading competitors in the market.The report includes information about the key vendors in the market.The report provides a complete overview of each company, including its profile, revenue generation, cost of goods, and products manufactured.The report presents the facts and figures about market competitors, alongside the viewpoints of leading market players.A market report includes details on recent market developments, mergers, and acquisitions involving the key players mentioned.

Access full Report Description, TOC, Table of Figure, Chart, etc.-https://reportocean.com/industry-verticals/sample-request?report_id=BWCC433

About Report Ocean:

We are the best market research reports provider in the industry. Report Ocean believes in providing quality reports to clients to meet the top line and bottom line goals which will boost your market share in todays competitive environment. Report Ocean is a one-stop solution for individuals, organizations, and industries that are looking for innovative market research reports.

Get in Touch with Us:Report Ocean:Email: sales@reportocean.comAddress: 500 N Michigan Ave, Suite 600, Chicago, Illinois 60611 UNITED STATES Tel: +1 888 212 3539 (US TOLL FREE)Website: https://www.reportocean.com/

Read this article:
Live Cell Imaging Market Size, Future Trends, Current Growth 2022, Emerging Technologies, Global Regions with Industry Share Analysis, Gross Margin,...

Cell Biology

Senior Kuziez named Marshall Scholar – The Source – Washington University in St. Louis Newsroom

Washington University in St. Louis senior Abdullah Kuziez, 21, has received the prestigious Marshall Scholarship, which provides American students the opportunity to earn an advanced degree in the United Kingdom. Kuziez plans to earn a masters degree in biomedical engineering at the University of Oxford as part of his ongoing search for cancer treatments that are both effective and accessible.

Oxford offers the singular opportunity to investigate the intersection of my passion for cancer science and synthetic biology, Kuziez said. I am deeply passionate about cancer therapy and research, a field which encompasses macro- and microscale interventions, from 100-meter accelerators to the molecular disruption of cancer metabolism. This degree will enable me to better understand these varied approaches and innovate my own.

The Marshall Scholarship is among the most selective in academia. Every year, approximately 1,000 endorsed applicants compete for an average of 45 slots. Kuziez is Washington Universitys seventh Marshall Scholar.

Kuziez, of Ballwin, Mo., is majoring in biophysics and biochemistry in Arts & Sciences and minoring in computer science at the McKelvey School of Engineering.

Kuziez is an Ervin Scholar and a member of Washington University for Undergraduate Socioeconomic Diversity, the Muslim Student Association and numerous other organizations. Kuziez also is deeply committed to the St. Louis community, providing comfort to cancer patients at Siteman Cancer Center and teaching AP chemistry to students at Soldan International High School.

The child of Syrian immigrants, Kuziez also teaches Arabic to local children and volunteers at the International Institute of St. Louis, where he helps Syrian refugees adjust to their new life in St. Louis.

Chancellor Andrew D. Martin said Kuziez embodies the best of Washington University.

Abdullah is a leader on campus, in the lab and in the community, Martin said. He is very deserving of this honor and will undoubtedly thrive as a Marshall Scholar at Oxford.

Kuziez chose to study cancer for a range of personal and pragmatic reasons. Kuziezs beloved grandfather died of cancer when Kuziez was in high school, a loss he still mourns. Relatively well funded, cancer research also provides a great opportunity to save a great number of lives, as cancer is among the leading causes of death worldwide, accounting for nearly 10 million deaths in 2020.

Kuziez, a true polymath, also is drawn to the field because it leverages so many disciplines, from quantum mechanics to molecular biology.

I dont want to ferret myself away in a single nook, Kuziez said. I really enjoy science for its connectedness, the way different fields interact and overlap with one another to tell a greater narrative.

Kuziez began studying cancer as a high school junior in the Optical Radiology Lab of Samuel Achilefu, the Michel M. Ter-Pogossian Professor of Radiology at Washington University School of Medicine. There, Kuziez first learned the applications of thermophoresis and how to synthesize photoactivated nanoparticles. He also discovered that science is an international endeavor.

In that lab alone, over 15 countries from all the continents were represented, Kuziez said. Science transcended borders; it was a community of knowledge that bridged nationality, language and culture. I realized that international collaboration was part and parcel of transformative research.

Kuziez also has worked at Argonne National Laboratory, where he researched the development of a carbon ion accelerator to treat resistant tumors, and the Mukherji lab for systems cell biology at Washington Universitywhere he explores the biophysical principles of organelle regulation, knowledge that could help treat aggressive cancers driven by organelle dysfunction.

Kuziezs mentors said they are amazed by the breadth and depth of his academic talents and his willingness to try new approaches.

To an unusual degree for an undergraduate, Abdullah has a strong sense of how his talents in mathematical thinking can be useful in biomedical research, as both a primary tool to carry out the techniques of computational biology research, but also as a way of thinking about modeling complex systems, wrote Shankar Mukherji, assistant professor of physics in Arts & Sciences, in his recommendation.

As the medical sciences are undergoing a transformation wrought by an increasing focus on quantitative thinking and methods, Abdullahs grasp of this area will offer a unique perspective to the Marshall Scholar community, added Mukherji, who also holds a joint appointment in cell biology and physiology at the School of Medicine.

He is kindhearted, decisive and inspiring, Achilefu said in his recommendation. He leads by example and shares his talents freely with those who need his support. Abdullah is highly creative, innovative, hardworking and self-motivated.

After Oxford, Kuziez plans to earn his MD/PhD and ultimately hopes to find a way to modify gene systems to treat cancer. Any solution that does not consider the culture and resources of its users is no solution at all, Kuziez said.

Who can afford these treatments? Who can access these technologies,Kuziez said. I really take a holistic approach to these questions. Growing up in St. Louis as the child of immigrants, I have witnessed how disparities can impact health outcomes. I want to design therapies for a global audience that are equitable for all.

See the original post here:
Senior Kuziez named Marshall Scholar - The Source - Washington University in St. Louis Newsroom

Cell Biology

Tenure-Track Professorships – Centre for Molecular Biology job with UNIVERSITY OF VIENNA | 274778 – Times Higher Education (THE)

Open to new ideas. Since 1365. The University of Vienna is a research university with high international visibility and a wide range of degree programmes. We are committed to basic research that is open to applications and to research-led teaching, as well as to the dialogue with economy and society. That way, the University of Vienna contributes to the education of future generations and to the societys ability to innovate. The appointment of particularly qualified researchers to university professors is an important strategy of the University of Vienna. Become part of this vibrant and future-oriented organisation.

Tenure-Track Professorships

Centre for Molecular Biology Mechanistic Cell Biology Structural Biology

Full details and the application deadline can be found at: tt-professuren.univie.ac.at/en

Classification according to the Collective Bargaining Agreement for University Staff: job group A1.

The salary will be individually negotiated under consideration of the previous career development and the current income situation.

Classification according to the Collective Bargaining Agreement for University Staff: section 49, job group A2. We offer the opportunity to obtain a permanent position and eventual promotion to full professor. The successful candidate is hired as Assistant professor for a maximum duration of six years. If the candidate meets the conditions stipulated in the qualification agreement, the assistant professor is promoted to tenured associate professor, i.e. obtains a permanent position. Associate professors can be promoted to full professor through a university-internal competitive procedure.

The University of Vienna pursues a non-discriminatory employment policy and values equal opportunities, as well as diversity (diversity.univie.ac.at). The University puts special emphasis on increasing the number of women in senior and in academic positions. Given equal qualifications, preference will be given to female applicants. ability to innovate. The appointment of particularly qualified researchers to university professors is an important strategy of the University of Vienna. Become part of this vibrant and future-oriented organisation.

See original here:
Tenure-Track Professorships - Centre for Molecular Biology job with UNIVERSITY OF VIENNA | 274778 - Times Higher Education (THE)

Cell Biology

Postdoctoral Research Associate in Macrophage Biology job with KINGS COLLEGE LONDON | 274566 – Times Higher Education (THE)

Job description

An exciting new opportunity has arisen within the Laboratory of Macrophage Biology at Kings College London, headed by Dr Subhankar Mukhopadhyay, based within the Peter Gorer Department of Immunobiology at Guys hospital campus. This is a full-time post, initially for 18 months, with a potential for extension.

The project will utilise a human induced pluripotent stem cell (iPSC) derived macrophage model to study the molecular control of human macrophage function in health and disease. First, the project will develop novel protocols for generating various tissue-resident and activated macrophage populations. Secondly, it will investigate how natural genetic variations, especially the disease-causing rare mutations, influence macrophage function during infection, inflammation and cancer.

The project will utilise a variety of cutting edge cellular and molecular techniques, including modern genome editing techniques, patient cohorts/CRISPR based large scale functional genomics screens, coupled with in-depth mechanistic assays. There will be ample scope for training, developing novel techniques, improving publication portfolio, and career development through new line of research.

We are looking for a highly motivated early-career post-doctoral researcher who has a keen interest, strong technical background and publication record in innate immunity/ macrophage biology. This position is ideal for future fellowship applicants who will be soon ready to apply for external fellowships.

Informal discussion to learn more about this position before application is strongly encouraged.

This post will be offered on an a fixed-term contract for 18 months

This is a full-time post - 100% full time equivalent

Key responsibilities

The above list of responsibilities may not be exhaustive, and the post holder will be required to undertake such tasks and responsibilities as may reasonably be expected within the scope and grading of the post.

Skills, knowledge, and experience

The successful candidate must have in-depth knowledge and demonstrable technical skills in primary human/murine macrophage culture and associated functional assays. In addition, technical knowledge in multi-colour flow cytometry, QPCR, Western blot, immunofluorescent/confocal microscopy is required.

Experience in iPSC derivation, maintenance and differentiation into immune cell lineages, CRISP/Cas9 based genome editing and bioinformatics skills for large scale transcriptomic and proteomic data analysis will be highly advantageous but not essential. Necessary training will be provided for these techniques.

Essential criteria

1. PhD in innate immunity, stem cell biology or related field

2. Demonstrable technical skills common immunology, cell biology and molecular biology techniques related to macrophage biology, innate immunity anjobd inflammation

3. Strong publication track record

4. Ability to perform experiments independently with minimum supervision and generate high-quality and reproducible data

5. Excellent written and verbal scientific and non-scientific communication skills are essential, and these must be clearly demonstrated through specific examples during application and interview

6. Excellent record keeping and time management skills and ability to work under tight deadlines and rapidly changing priorities

7. Ability to work both independently and as part of a team in a friendly, collegial manner promoting the collective goal of the team

Desirable criteria

1. Experience in human iPSC models, gene editing, functional genomics screen

2. Experience in handling patient blood and generation of primary macrophages

3. Experience in in vivo macrophage function in murine models and Home office personal license

4. Bioinformatic skill and large scale data analysis

*Please note that this is a PhD level role but candidates who have submitted their thesis and are awaiting award of their PhDs will be considered. In these circumstances the appointment will be made at Grade 5, spine point 30 with the title of Research Assistant. Upon confirmation of the award of the PhD, the job title will become Research Associate and the salary will increase to Grade 6.

Further information

This post is subject to Disclosure and Barring Service and Occupational Health clearance.

View post:
Postdoctoral Research Associate in Macrophage Biology job with KINGS COLLEGE LONDON | 274566 - Times Higher Education (THE)

Cell Biology

Oxford Spin-out Alethiomics launches to advance its multi-omics target discovery pipeline in blood cancer, as highlighted in ASH plenary – PRNewswire

- Spin-out from University of Oxford built on a decade of world-leading research on blood cancers and breakthrough innovation in single-cell multi-omic analysis by founders Professor Adam Mead and Professor Beth Psaila

- 6m seed financing from science business builder Oxford Science Enterprises

- Novel therapeutics, based on targets discovered using the TARGET-seq platform, will be developed to address unmet need in blood cancers

- TARGET-seq highlighted in a plenary session at the American Society of Haematology (ASH) meeting on 12 December

-Led by pharma/biotech experienced Board and Management, Dr Mark Throsby, Chairman and Dr Edward Ainscow, CSO

OXFORD, England, Dec. 15, 2021 /PRNewswire/ -- Alethiomics, a drug discovery company focused on developing targeted therapies to treat a family of blood cancers called myeloproliferative neoplasms (MPNs), launched today, backed by 6m seed financing from Oxford Science Enterprises.

A spin-out from the University of Oxford, the company is based on world-leading discoveries in clinical haematology and single-cell multi-omics by its founders, Professor Adam Mead and Professor Beth Psaila. Mark Throsby Ph.D. has been appointed as Chairman and Edward Ainscow Ph.D. has joined as Chief Scientific Officer (CSO).

MPNs are a group of chronic blood cancers that begin with mutations occurring in cancer stem cells in the bone marrow. Currently available treatments, for example JAK2 inhibitors, provide symptomatic benefit, but do not tackle the underlying disease drivers meaning that many patients have a persistent burden of disease and remain at risk of disease progression.

Identifying new drug targets within these mutant cells is critical to developing targeted and curative therapies. Alethiomics' founders have pioneered the use of single-cell multi-omic approaches to better understand the biology of mutant-positive stem cells in MPNs and to discover novel molecular targets as the basis for drug discovery. They have also developed bespoke platforms for target validation to accelerate successful translation to the clinic.

Prof. Mead said:"Despite tremendous advances in oncology, the quality of life and outcome for patients with many aggressive cancers remains poor. It is now clear that precision treatments targeted at specific driver mutations in cancer-initiating cells are required. Current approaches to single-cell tumour analysis are unable to resolve both cellular and mutational heterogeneity. The Alethiomics TARGET-seq platform simultaneously detects DNA mutations, the RNA transcriptome and cell surface proteins from individual cells to provide a holistic understanding of pathologies and more intelligent target identification.

Prof. Psaila added:"Our initial focus is on the most sinister MPNs, for which current treatments are really inadequate and many of our patients still suffer very poor outcomes. We are really excited to have founded Alethiomics and to be recruiting an experienced and dynamic team, enabling us to translate our discoveries in novel target identification into precision medicines to improve the lifespan and quality of life for the patients we care for in the clinic."

The breakthrough potential of the founders' research is underlinedby the fact that work using TARGET-seq, led byProfessor Mead,was selected for the Plenary Session at one of most prestigious scientific presentations in haematology; the American Society of Hematology (ASH) annual meeting1.

The seed financing will be used to establish Alethiomics' research operations at the Oxford BioEscalator, to advance its pipeline of programmes in MPNs, and to industrialise the company's proprietary TARGET-seqdrug discovery and target prioritisation platform.

Claire Brown, PhD, MBA, Life Sciences Partner at Oxford Science Enterprises said:"We are tremendously impressed by the unparalleled expertise in haematological cancer of Prof. Mead and Prof. Psaila, and their passion for bringing new therapies to the clinic to benefit patients. We look forward to buildingon their foundational discoveries and to developing clinical programmes and new therapies that deliver on the early promise of the technology."

Co-founders, Adam and Beth, will act as consultants to Alethiomics and serve on the Scientific Advisory Board, whilst continuing to lead their research groups at the MRC Weatherall Institute of Molecular Medicine, Radcliffe Department of Medicine, Universityof Oxford alongside their clinical practices in the Department of Haematology at Oxford University Hospitals NHS Trust.

Chairman Dr Mark Throsby is a biopharmaceutical executive with extensive research experience and a track record of innovation and execution. He is an expert in antibody engineering and immunology with over two decades of commercial experience gained in pharma and biotech at Crucell NV and Merus NV. Alongside his role at Alethiomics he acts as COO/CSO of Gadeta BV and serves on the Board of Ona Therapeutics.

CSO Dr Ed Ainscow brings two decades of experience working on innovative approaches to early drug discovery in both pharma and biotech. He joins from Carrick Therapeutics Ltd where he has been Chief Technology Officer for the past five years.

Alethiomics foundational research has been supported by academic and charitable grants including the support of Cancer Research UK, which becomes a minority shareholder in the company.

1. ASH Plenary Session Information

Title:Single-Cell Multi-Omics Reveals the Genetic, Cellular and Molecular Landscape ofTP53Mutated Leukemic Transformation in MPNPlenary Scientific Session:Hematology Disease Topics & Pathways:Fundamental Science, Genomics, Translational Research, Hematopoiesis, Biological ProcessesPresenter: Dr Rodriguez-MeiraTiming:Presented on Sunday, December 12, 2021, 2:00 PM-4:00 PM ESTPaper:https://ash.confex.com/ash/2021/webprogram/Paper150191.html

Notes to Editors:

About Alethiomics

Alethiomics Ltd is a pre-clinical biotech company harnessing the power of single cell multi-omic technology to discover and develop life changing treatments for patients with blood cancer. A spin-out from the University of Oxford, Alethiomics was co-founded with support from Oxford University Innovation in 2021 by Prof. Adam Mead and Prof Bethan Psaila, both academic clinicians and expert haematologists.

With R&D facilities in Oxford UK, the company is financed by seed investment from Oxford Science Enterprises.

Find out more: http://www.alethiomics.com | LinkedIn| Twitter

About Oxford Science Enterprises

Oxford Science Enterprises is a Science Business Builder, committed to helping solve the world's toughest problems for more people, in more places, faster.The companydoes this by transforming world-leading science into world-changing businesses, partnering the best scientists from the world's best university with the best business brains. Oxford Science Enterprises grows its companies with care and expertise, investing for real-world impact, not only financial returns, and re-investing proceeds back into the next generation of original research and world-changing businesses.

Since 2015, the company has received an automatic stake in all Oxford University science spinouts and has taken a leading role in creating and building enterprises that addressproblems that affect people in life-changing ways: theirhealth, the availability of food, the survival of the planet.

Find out more:oxfordscienceenterprises.com|Twitter|LinkedIn

MRC Weatherall Institute of Molecular Medicine(MRC WIMM)

The MRC WIMM was founded in 1989 by Sir David Weatherall, and was the first institute of its kind in the UK to link basic research in molecular and cell biology with clinical research. The MRC WIMM is a strategic partnership between theMedical Research Counciland theUniversity of Oxford. The institute brings together over 500 researchers, staff and students now focusing on five research areas: rare genetic diseases, haematology, immunology and infection, stem cell and developmental biology, and cancer biology.

Find out more:https://www.imm.ox.ac.uk/

Radcliffe Department of Medicine (RDM)

The RDMis one of the two main departments of medicine at the University of Oxford, and aims to tackle some of the world's biggest health challenges by integrating innovative basic biology with cutting edge clinical research. The RDM has internationally renowned programmes in a range of areas including cardiovascular sciences, diabetes and endocrinology, immunology, haematology and pathology.

Find out more:https://www.rdm.ox.ac.uk/

About Cancer Research UK

Cancer Research UK is the world's leading cancer charity dedicated to saving lives through research. It's pioneering work into the prevention, diagnosis and treatment of cancer has helped save millions of lives. Cancer Research UK has been at the heart of the progress that has already seen survival in the UK double in the last 40 years. Today, 2 in 4 people survive their cancer for at least 10 years. Cancer Research UK's ambition is to accelerate progress so that by 2034, 3 in 4 people will survive their cancer for at least 10 years. Cancer Research UK supports research into all aspects of cancer through the work of over 4,000 scientists, doctors and nurses. Together with its partners and supporters, Cancer Research UK's vision is to bring forward the day when all cancers are cured.

Find out more:www.cancerresearchuk.org

Follow us on Twitterand Facebook.

For Further information, please contact:

At the CompanyEd Ainscow, CSO, [emailprotected]

Media EnquiriesSue Charles, Charles Consultants, [emailprotected], +44 (0)7986 726585

SOURCE Alethiomics

See original here:
Oxford Spin-out Alethiomics launches to advance its multi-omics target discovery pipeline in blood cancer, as highlighted in ASH plenary - PRNewswire

Genetics

Unlocking the genetic code of congenital heart disease – Cosmos Magazine

One in every 100 babies is born with a congenital heart disease (CHD), which is a major cause of death in newborns. Despite this, the genetics of the disease are not well understood, which hinders accurate prenatal genetic testing.

Now, researchers from Monash University have uncovered more than 1,300 genes that are linked to CHD, included some that were previously unknown. This may help improve prenatal genetic testing for foetuses.

[Previous methods] focused on screening genes that are present in the heart only an approach that often overlooks genes that are present in other tissues as well, despite still playing important roles in heart development, says Dr Hieu Nim from Australian Regenerative Medicine Institute, the first author of the study, published in Genome Biology, the team expanded the repertoire of genes that are potentially at play in heart development and/or CHD.

These could comprise many of the missing congenital heart disease genes, but have been, to date, discounted because they are not unique to the heart, says Associate Professor Mirana Ramialison, also of Monash Universitys Australian Regenerative Medicine Institute and the Murdoch Childrens Research Institute.

Get an update of science stories delivered straight to your inbox.

Once the gene repertoire had been identified, the team used the fruit fly a well-established model organism in biology to determine the impact of the novel genes. This is because 75% of the disease-causing genes in humans are also found in a similar form in the fruit fly, so we can get a quick snapshot of the consequences of mutated genes.

The fruit fly experiments revealed a long list of high-quality candidate genes for causing heart abnormalities in humans, giving real insight into just how susceptible this organ is to genetic mutations, says Dr Travis Johnson from Monash Universitys School of Biological Sciences.

Understanding genetic screening and disease is incredibly complex, so Johnson cautions that the new information isnt ready for use yet in prenatal genetic screening for CHD.

We now need to conduct functional studies on all of these genes in animal experiments to determine what they actually do, so its early days, he explains. But we now have an excellent starting point.

Theres never been a more important time to explain the facts, cherish evidence-based knowledge and to showcase the latest scientific, technological and engineering breakthroughs. Cosmos is published by The Royal Institution of Australia, a charity dedicated to connecting people with the world of science. Financial contributions, however big or small, help us provide access to trusted science information at a time when the world needs it most. Please support us by making a donation or purchasing a subscription today.

Original post:
Unlocking the genetic code of congenital heart disease - Cosmos Magazine

Genetics

Predictive Genetic Testing and Consumer/Wellness Genomics Market Analysis and Forecast to 2025 – BioSpace

Predictive genetic testing are used to identify gene mutations pertaining to the disorders that surface at a considerably later stage in life after birth. These tests are particularly beneficial for people from a family with a history of genetic disorder, although they themselves show no symptoms of the disorder at the time of testing. Genetic testing promises to revolutionize the healthcare sector, providing crucial diagnostic details related to diverse verticals such as heart disease, autism, and cancer. As the healthcare sector touches new peaks, the global predictive genetic testing and consumer/wellness genomics market is projected to expand at a healthy growth rate during the forecast period of 2017 to 2025.

This report on the global market for predictive genetic testing and consumer/wellness genomics analyzes all the important factors that may influence the demand in the near future and forecasts the condition of the market until 2025. It has been created using proven research methodologies such as SWOT analysis and Porters five forces. One of the key aspect of the report is the section on company profiles, wherein several leading players have been estimated for their market share and analyzed for their geographical presence, product portfolio, and recent strategic developments such as mergers, acquisitions, and collaborations.

Get Brochure of the Report @ https://www.tmrresearch.com/sample/sample?flag=B&rep_id=1274

The global predictive genetic testing and consumer/wellness genomics market, on the basis of test type, can be segmented into predictive testing, consumer genomics, and wellness genetics. The segment of predictive testing can be sub-segmented into genetic susceptibility test, predictive diagnostics, and population screening programs, whereas the segment of wellness genetics can be further divided into nutria genetics, skin and metabolism genetics, and others. By application, the market can be segmented into breast and ovarian cancer screening, cardiovascular screening, diabetic screening and monitoring, colon cancer screening, Parkinsons or Alzheimers disease, urologic screening or prostate cancer screening, orthopedic and musculoskeletal screening, and other cancer screening. Geographically, the report studies the opportunities available in regions such as Asia Pacific, Europe, North America, and the Middle East and Africa.

Global Predictive Genetic Testing and Consumer/Wellness Genomics Market: Trends and Opportunities

Increasing number of novel partnership models, rapidly decreasing cost of genetic sequencing, and introduction of fragmented point-solutions across the genomics value chain as well as technological advancements in cloud computing and data integration are some of the key factors driving the market. On the other hand, the absence of well-defined regulatory framework, low adoption rate, and ethical concerns regarding the implementation, are expected to hinder the growth rate during the forecast period. Each of these factors have been analyzed in the report and their respective impacts have been anticipated.

Currently, the segment of predictive genetic cardiovascular screening accounts for the maximum demand, and increased investments in the field is expected to maintain it as most lucrative segment. On the other hand, more than 70 companies are currently engaged in nutrigenomics, which is expected to further expand the market.

Get Table of Content of the Report @ https://www.tmrresearch.com/sample/sample?flag=T&rep_id=1274

Global Predictive Genetic Testing and Consumer/Wellness Genomics Market: Regional Outlook

Owing to robust healthcare infrastructure, prevalence of cardiovascular diseases, and high adoptability rate of new technology makes North America the most lucrative region, with most of the demand coming from the country of the U.S. and Canada. Several U.S. companies hold patents, which further extends the outreach of the market in the region of North America.

Companies mentioned in the research report

23andMe, Inc, BGI, Genesis Genetics, Illumina, Inc, Myriad Genetics, Inc, Pathway Genomics, Color Genomics Inc., and ARUP Laboratories are some of the key companies currently operating in global predictive genetic testing and consumer/wellness genomics market. Various forms of strategic partnerships with operating company and smaller vendors with novel ideas helps these leading players maintain their position in the market.

TMR Research is a leader in developing well-researched reports. The expertise of the researchers at TMR Research makes the report stand out from others. TMR Research reports help the stakeholders and CXOs make impactful decisions through a unique blend of innovation and analytical thinking. The use of innovation and analytical thinking while structuring a report assures complete and ideal information of the current status of the market to the stakeholders.

Get Premium Customized Report @ https://www.tmrresearch.com/sample/sample?flag=CR&rep_id=1274

The reports offer answers to the top 7 questions that revolve around the growth of the market

About TMR Research

TMR Research is a premier provider of customized market research and consulting services to business entities keen on succeeding in todays supercharged economic climate. Armed with an experienced, dedicated, and dynamic team of analysts, we are redefining the way our clients conduct business by providing them with authoritative and trusted research studies in tune with the latest methodologies and market trends.

Contact:

Rohit Bhisey

TMR Research,

3739 Balboa St # 1097,

San Francisco, CA 94121

United States

Tel: +1-415-520-1050

Visit Site: https://www.tmrresearch.com/

Read the original post:
Predictive Genetic Testing and Consumer/Wellness Genomics Market Analysis and Forecast to 2025 - BioSpace

Genetics

Professor Ross Houston to join BMK Genetics in 2022 – The Fish Site

Professor Houston is well known in the aquaculture genetics and animal breeding communities. He began his career with a PhD in pig genetics at the University of Aberdeen in 2004 before moving into salmon genetics in a postdoc position at Roslin. Ever since, he has built an international reputation in the field, including discovering a major QTL associated with resistance to Infectious Pancreatic Necrosis in 2008, which remains an exemplar of using genetics to help control disease and improve health.

Houston leads several high-profile international aquaculture research projects focussing on application of genomics and genome editing technologies to improve disease resistance. He has authored and co-authored over 100 peer-reviewed publications and has received several awards for his contributions to the scientific community.

In the role of Director of Innovation, he will lead BGs strategic development of innovation and R&D to support business growth and secure the companys competitive advantages. He will also develop and lead collaborative projects both internally and externally, including harnessing synergies on innovation across the field of genetics, health, and nutrition within the Benchmark Group as a member of Benchmarks cross-divisional Innovation Board.

The new role will also involve product development for the Benchmark Genetics in-house breeding programmes in salmon, shrimp, and tilapia. Finally, Ross will assist in expanding the portfolio of external clients for the applied genetics consultancy services, of which Benchmark Genetics has been in the forefront for more than three decades.

Dr Morten Rye, Director of Genetics in Benchmark, says: Getting Ross Houston on board significantly strengthens our genetics R&D capacities and is also a great acknowledgement to the reputation of our organisation. Genetics technologies are rapidly advancing, and I am convinced that having Ross to lead our strategic development of innovation and R&D will place Benchmark in the forefront of this progress.

Ross Houston is excited about the new position and adds: I have been collaborating with Benchmark scientists for several years, and I am impressed about how the genetics business area has developed during this time. Im very motivated by translating the latest scientific developments into commercial practice, to benefit the organisation as well as enhancing the sustainability of the industry.

More here:
Professor Ross Houston to join BMK Genetics in 2022 - The Fish Site